By Helena Strigård, CEO and Founder
November 12, 2026
Mark Quick, Partner at Flerie, CEO of Nanologica
October 23, 2026 — Flerie AB’s portfolio company, Nanologica, has appointed Mark Quick as its new CEO, while he continues his role as Partner at Flerie. Current CEO Andreas Bhagwani will transition to General Manager of Nanologica's purification and separation business. This leadership change coincides with an updated strategy and a rights issue of approximately SEK 110.5 million.
Mark Quick brings a wealth of experience from the pharmaceutical manufacturing sector, having held senior leadership positions at Recipharm. His prior involvement as a member of Nanologica’s Board of Directors has provided him with a deep understanding of the company’s operations and strategic direction.
“I have been supporting Nanologica for quite a few years in the background and have always felt it was a company on the brink of commercial breakthrough. Now we finally have a stable silica supply we are at a pivotal moment in our journey," Quick stated. "Our chromatography business is now poised to benefit from the GLP1 growth as we make a key product in their purification. This coupled with the heritage and depth of knowledge of Syntagon gives us a solid base to move towards a sustainable business. After only a few days in the business, it is clear that the team is extremely experienced and competent and I am confident of success in the revised strategy that the board has implemented,”
To deliver the updated strategy Nanologica has announced a partially guaranteed rights issue of approximately SEK 110.5 million to support its initiatives.
Ted Fjällman, CEO of Flerie, expressed confidence in Quick's leadership: “Mark’s insights from his board role equip him uniquely to guide Nanologica through its next phase of growth.”
Quick will officially assume the CEO position once the Swedish Companies Registration Office grants an exemption from the residency requirement for a CEO.